Trending Topics

and/or

87 Trending Topics found

FDA Expands Use of HPV Vaccine: What It Means in the Fight against Cancer

The US Food and Drug Administration has updated its recommendations for the use of Gardasil 9, the vaccine that protects against human papillomavirus (HPV), to include people age 27 to 45. Previously, Gardasil 9 was only approved for use in those between age nine and 26. 

  • Thursday, October 18, 2018

World-Renowned Immunologist Michel Sadelain Wins Pasteur-Weizmann/Servier Prize

Michel Sadelain, MD, PhD, Director of the Center for Cell Engineering at MSK, has been awarded the Pasteur-Weizmann/Servier International Prize. Dr. Sadelain was chosen in recognition of his pivotal research demonstrating the therapeutic potential of engineered T cells.

  • Tuesday, October 16, 2018

New Nanosensor Finds Long-Term Effects of a Bad Diet on the Liver

After developing a noninvasive nanosensor to detect the progression of fatty liver disease in mice, researchers at the Sloan Kettering Institute have determined that there is a long-term effect on liver macrophages from eating a high-fat and high-sugar diet, even after switching back to a normal diet.

  • Friday, October 12, 2018

Times Square Goes Gold to Raise Awareness for Pediatric Cancer

Recently, dozens of survivors, their parents, and members of the Memorial Sloan Kettering Cancer Center (MSK) Department of Pediatrics joined the Times Square Advertising Coalition to turn the bright lights of Times Square gold to raise awareness for pediatric cancer.

  • Thursday, October 11, 2018

Nobel Prize in Medicine Awarded to Former MSK Immunologist, James Allison

The Nobel committee this week awarded its Prize in Physiology or Medicine to work focused on cancer, specifically, James P. Allison and Tasuku Honjo for their work on immune checkpoint blockade. Dr. Allison was a member of the Sloan Kettering Institute from 2004 to 2012.

  • Thursday, October 4, 2018

Fecal Transplants Proven to Restore Health-Promoting Bacteria

A randomized clinical trial at Memorial Sloan Kettering Cancer Center (MSK) has shown that fecal microbiota transplants (FMTs) can reestablish the health-promoting bacteria that are often damaged by intense antibiotic treatment in people who have stem cell or bone marrow transplants for blood cancer.

  • Friday, September 28, 2018

Sloan Kettering Institute Researchers Look Beyond DNA to Identify Cancer Drivers

Researchers at the Sloan Kettering Institute have found that changes in an information-carrying molecule called messenger RNA (mRNA) can inactivate the functions of tumor suppressor genes and thereby promote cancer. The findings pinpoint previously unknown drivers of the disease, indicating that cancer diagnostics need to go beyond the analysis of DNA mutations.

  • Monday, August 27, 2018

Memorial Sloan Kettering Researchers Build a New Model of Genetically Engineered Immune Cells That May Combat Solid Tumors in the Future

Scientists at Memorial Sloan Kettering Cancer Center (MSK) announced that they have built a new model of genetically engineered immune cells in mice that may allow them to fight solid tumors.

  • Monday, August 13, 2018

MSK Researchers Have Identified a Doubling Chromosome That Can Help Predict Outcomes in People with Cancer

Experts at Memorial Sloan Kettering Cancer Center (MSK) have identified genome doubling in cancer and have correlated it to a worse prognosis across cancer types. Using MSK-IMPACT™ to analyze matched tumor and normal DNA, MSK researchers were able to identify an abnormality in tumors known as genome doubling. This doubling occurs in 28 percent of all cancers and could have significant implications for treatment options in the future.

  • Monday, July 16, 2018

Findings from People with Acute Myeloid Leukemia Point to a New Understanding of Drug Resistance

Drug resistance is a formidable challenge in cancer treatment. A drug called enasidenib (Idhifa®) was approved by the US Food and Drug Administration last year for the treatment of people with a form of acute myeloid leukemia (AML) that’s driven by a mutation in the gene IDH2. About 15 percent of people with AML have this mutation. Research led by Memorial Sloan Kettering Cancer Center (MSK) reports that people who take enasidenib can develop resistance to it — in a way never seen before. Enasidenib works differently than most cancer drugs. Rather than killing leukemia cells, it turns them into normal blood cells. The discovery of this unique resistence may lead to more-precise treatments for people with AML in the future.

  • Thursday, July 5, 2018